Wegovy 1.5 mg Tablets – Semaglutide 30 Tablets

Wegovy 1.5 mg tablets contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Novo Nordisk developed Wegovy for weight management and cardiovascular risk reduction in eligible adults.

The 1.5 mg tablet provides the starting strength for the current Wegovy oral dosing schedule. The U.S. prescribing information lists Wegovy tablets in 1.5 mg, 4 mg, 9 mg and 25 mg strengths. The 1.5 mg presentation comes in a 30-tablet bottle.

Wegovy tablets work through the GLP-1 receptor pathway. Semaglutide can affect appetite regulation, food intake and glucose metabolism. Patients should use Wegovy according to the prescribing information provided by their healthcare professional.

The current U.S. prescribing information starts Wegovy tablets at 1.5 mg once daily for 30 days. It then increases the dose at 30-day intervals according to the approved escalation schedule, with 25 mg once daily as the recommended maintenance dose for the listed adult indications. Patients should not change their dose without medical guidance.

Wegovy tablets received U.S. approval for oral semaglutide treatment in December 2025, and Novo Nordisk announced broad U.S. availability in January 2026. The European Commission also granted authorization for the Wegovy pill in July 2026. Regulatory status can differ between countries, so patients should check the requirements that apply in their location.

Wegovy has important safety information and contraindications. The current U.S. prescribing information includes a boxed warning concerning thyroid C-cell tumors and contraindicates Wegovy in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Patients should review the complete prescribing information before treatment.

Wegovy is a prescription medicine. A qualified healthcare professional should determine whether treatment is appropriate for an individual patient. This product information does not replace professional medical advice, diagnosis or treatment.

Official Wegovy Information

For complete prescribing information, warnings, contraindications, dosage information and other safety details, review the current FDA Wegovy prescribing information.

You can also review official information from Novo Nordisk regarding the Wegovy pill and its regulatory approvals.